Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Begonya Comin-Anduix, Ph.D.
Begonya Comin-Anduix, Ph.D.

Affiliation(s):

Assistant Professor, Department of Surgery, Surgical Oncology
Member, JCCC Tumor Immunology Program Area

Contact Information:

Phone:
(310) 267-2211
Email:

Scientific Interest(s):

Dr. Begonya Comin-Anduix’s research focuses on two areas: optimizing immune monitoring techniques and studying approaches to enhance the T-cell responses to human metastatic melanoma.

Comin-Anduix studies the optimization, development, and validation of quantitative immune monitoring methods at a single cell level. Existing available methods require large samples, which are difficult to acquire from melanoma patients. Therefore, she collaborates with engineers from the California Institute of Technology to microscale quantitative immune monitoring methods optimized in her research.

Tumor infiltrating lymphocytes (TIL) may be the key for improving immunotherapy in melanoma patients. Previous work of Comin-Anduix and colleagues shows that antigen-specific cytotoxic T-lymphocytes are more abundant in regressing tumors than in progressing lesions and peripheral blood of melanoma patients. Unpublished results of her research show that lymphocytes found in the tumor are phenotypically different from those found in peripheral blood. Thus, the other focus area of her laboratory characterizes and optimizes TILs to improve T-cell response against melanoma.

Selected Cancer-Related Publications:

Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15;5(9):e12711.

Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct;33(8):759-68.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 1;15(19):6267-76. Epub 2009 Sep 29.

Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 1;6:22.

Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 1;12(1):107-16.